Halberd Corp.

Develop extra-corporeal treatments of disease

Recent News

  • Halberd Successfully Eliminates Excess Levels of Inflammatory Cytokines

    Jackson Center, Pennsylvania--(Newsfile Corp. - May 24, 2022) - Halberd Corporation (OTC Pink: HALB) researchers have demonstrated a protocol which allows for the precise level of elimination of a specific targeted cytokine from a homogeneous mixture of two different cytokines in a fluid. Several adverse health conditions are caused by excess quantities of particular components in blood or cerebral spinal fluid (CSF), such as proteins, cytokines, amino acids, etc. Elimination of excessive quantities of these elements is key...

    2022-05-24 8:00 AM EDT
  • Halberd Engages Professional Firm to Proceed with FDA Filings

    Jackson Center, Pennsylvania--(Newsfile Corp. - May 18, 2022) - Halberd Corporation (OTC Pink: HALB) has engaged the services of mdi Consultants, Inc. (mdi) to assist Halberd in navigating the U.S. Food and Drug Administration's (FDA) complex application and certification processes. mdi will guide Halberd on the FDA application and testing protocol and assist in filing the appropriate documents and disclosures with the FDA in each stage of the process. After numerous discussions, Halberd is confident that mdi is...

    2022-05-18 8:00 AM EDT
  • Halberd Submits Audited Financials; Files Form-10 as First Step to Up-List to OTCQB

    Jackson Center, Pennsylvania--(Newsfile Corp. - May 12, 2022) - Halberd Corporation (OTC Pink: HALB) submitted its fully audited financials through its fiscal second quarter and Form-10 to the SEC as its initial step to up-list from OTC-PINK to OTCQB on the OTC Markets exchange. Once Halberd's shares are qualified under the Securities Exchange Act of 1934 (the "34 Act"), Halberd will become a fully reporting issuer pursuant to Section 12(g) of the '34 Act. The OTCQB index...

    2022-05-12 8:00 AM EDT
  • Halberd CEO Letter

    Jackson Center, Pennsylvania--(Newsfile Corp. - April 25, 2022) - Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC: HALB)This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team.Q1 OVERVIEW AND ACHIEVEMENTS Halberd demonstrated elimination of the final two of the "Top Ten" antigens linked to neurodegenerative diseases.Halberd demonstrated that its antigen elimination process is able to selectively eliminate target antigens from cerebral spinal fluid (CSF).Halberd investigations revealed that it's proprietary Covid-19 antibody demonstrated a...

    2022-04-25 8:00 AM EDT
  • Halberd Eliminates E. Coli in 20 Minutes Vs. 7-10 Days with Conventional Antibiotics

    Jackson Center, Pennsylvania--(Newsfile Corp. - April 18, 2022) - Halberd Corporation (OTC PINK: HALB) demonstrated the efficacy of its patented extracorporeal methodology for treatment and eradication of disease states. The latest success was again extracorporeal elimination of E. coli bacteria from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro, in under 20 minutes. This compares to up to 10 days using conventional antibiotic treatments as the current standard of care. E. coli (Escherichia...

    2022-04-18 8:00 AM EDT
  • Halberd Entering the Medical Metaverse

    Jackson Center, Pennsylvania--(Newsfile Corp. - April 11, 2022) - Halberd Corporation (OTC PINK: HALB) announces plans to enter the Metaverse by the creation of non-fungible tokens (NFT's) to monetize certain intellectual properties of the company including but not limited to patents, patents pending, trade secrets, etc.Halberd is currently in negotiations to engage a team of experts in Metaverse with expertise in non-fungible tokens (NFT's) who can identify growth opportunities by monitoring the evolving marketplace, setting category strategy, and managing key...

    2022-04-11 8:00 AM EDT
  • Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression

    Jackson Center, Pennsylvania--(Newsfile Corp. - April 4, 2022) - Halberd Corporation (OTC Pink: HALB) demonstrated the extracorporeal elimination of C-Reactive Protein from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro. Halberd, encouraged by its recent success in eliminating all ten of the top antigens associated with PTSD (Post Traumatic Stress Disorder), CTE (Chronic Traumatic Encephalopathy) and numerous other neurodegenerative diseases, expanded their research to address elimination of the disease antigen associated with clinical depression -...

    2022-04-04 8:00 AM EDT
  • Infectious Disease Specialist Will Guide Halberd's Extracorporeal Elimination of Disease Antigens in Animals and Then Humans

    Jackson Center, Pennsylvania--(Newsfile Corp. - March 16, 2022) - Halberd Corporation (OTC Pink: HALB) announces its entry into the next stage of research. To guide it, having successfully eliminated the Top 10 Target Antigens associated with neurodegenerative diseases in vitro, Halberd is pleased to announce the addition of Ravi Venkata Durvasula, M.D., a renowned infectious disease specialist and educator, to its team of technical experts and consultants. Dr. Durvasula will guide Halberd's efforts in applying its patented extracorporeal...

    2022-03-16 8:00 AM EDT